Oragenics Inc.

Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more

Therapies aim to enhance lysosomal function to clear cholesterol and glycosphingolipids, mostly via small molecules

Plus Melvin becomes COO at Viridian and updates from Oragenics and Transine

Mark Shearman will join Editas Medicine Inc. (NASDAQ:EDIT) in June as EVP and CSO. Shearman currently serves as CSO of Applied Genetic Technologies Corp. (NASDAQ:AGTC). Kyowa Kirin Co. Ltd.

In the race to develop the next generation of COVID-19 vaccines, at least 22 vaccine programs are being developed with an intranasal route of administration.  Intranasal vaccines may provide